Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results
- PMID: 29080208
- DOI: 10.1007/s40261-017-0590-4
Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results
Abstract
Background: Alcohol dependence remains a major health problem from both a public health and clinical perspective. Harm reduction strategies have been increasingly recognized as suitable treatment goals. Nalmefene has been recently approved for this precise therapeutic indication after completion of phase III trials. However, more data from routine practice settings are needed in order to obtain evidence with high external validity. The aim of this study was to conduct a single-arm, phase IV study with alcohol-dependent outpatients starting nalmefene for the first time.
Methods: An observational, multisite, single-arm, phase IV study was conducted among adult alcohol-dependent outpatients who received nalmefene for the first time. The study consisted of four visits: baseline, 4 weeks (referred to as 1 month hereafter), 6 and 12 months. At each visit, drinking variables were obtained from the Timeline Followback regarding the previous month. Satisfaction with medication was also assessed for both patients and professionals, with the Medication Satisfaction Questionnaire. A repeated measures mixed model was performed for effectiveness analysis regarding drinking outcomes (reduction in total alcohol consumption and number of heavy drinking days). Regression analyses were performed in order to find predictors of response to nalmefene.
Results: A total of 110 patients were included, with 88 reporting data at the 1-month visit. On average, patients took nalmefene 68% of the days. The number of heavy drinking days decreased from 13.5 to 6.8 days/month, and total alcohol consumption decreased from 169 to 79 units. For both outcomes, significant reductions at 1 month were found, with no other significant variables reaching significance. Thirty-seven patients were considered medication responders, but given the high presence of low-risk drinkers in our sample, no significant predictors could be found. Satisfaction was globally high for both professionals and patients, and overall nalmefene was well tolerated, with no serious adverse events reported.
Conclusion: The data provided by this phase IV study suggest nalmefene is an effective, well-tolerated treatment for alcohol dependence in real-world, clinical settings.
Comment in
-
Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?Clin Drug Investig. 2018 Apr;38(4):385-386. doi: 10.1007/s40261-018-0628-2. Clin Drug Investig. 2018. PMID: 29476330 No abstract available.
-
Reply to Braillon et al.: Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?Clin Drug Investig. 2018 Apr;38(4):387-388. doi: 10.1007/s40261-018-0625-5. Clin Drug Investig. 2018. PMID: 29480453 No abstract available.
Similar articles
-
The More You Take It, the Better It Works: Six-Month Results of a Nalmefene Phase-IV Trial.J Clin Med. 2019 Apr 6;8(4):471. doi: 10.3390/jcm8040471. J Clin Med. 2019. PMID: 30959893 Free PMC article.
-
Nalmefene. Alcohol dependence: no advance.Prescrire Int. 2014 Jun;23(150):150-2. Prescrire Int. 2014. PMID: 25121147
-
A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.Eur Neuropsychopharmacol. 2013 Nov;23(11):1432-42. doi: 10.1016/j.euroneuro.2013.02.006. Epub 2013 Apr 3. Eur Neuropsychopharmacol. 2013. PMID: 23562264 Clinical Trial.
-
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Pharmacoeconomics. 2015 Aug;33(8):833-47. doi: 10.1007/s40273-015-0272-0. Pharmacoeconomics. 2015. PMID: 25851485 Review.
-
Nalmefene: a review of its use in the treatment of alcohol dependence.CNS Drugs. 2013 Sep;27(9):761-72. doi: 10.1007/s40263-013-0101-y. CNS Drugs. 2013. PMID: 23949908 Review.
Cited by
-
Kappa Opioid Signaling at the Crossroads of Chronic Pain and Opioid Addiction.Handb Exp Pharmacol. 2022;271:315-350. doi: 10.1007/164_2021_434. Handb Exp Pharmacol. 2022. PMID: 33547588 Free PMC article.
-
Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.Innov Clin Neurosci. 2019 May 1;16(5-6):15-21. Innov Clin Neurosci. 2019. PMID: 31440397 Free PMC article.
-
Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective.Int J Environ Res Public Health. 2023 Jan 19;20(3):1870. doi: 10.3390/ijerph20031870. Int J Environ Res Public Health. 2023. PMID: 36767234 Free PMC article. Review.
-
A systematic meta-epidemiologic review on nonabstinence-inclusive interventions for substance use: inclusion of race/ethnicity and sex assigned at birth/gender.Am J Drug Alcohol Abuse. 2024 May 3;50(3):276-290. doi: 10.1080/00952990.2024.2308087. Epub 2024 Feb 27. Am J Drug Alcohol Abuse. 2024. PMID: 38411974 Free PMC article.
-
The More You Take It, the Better It Works: Six-Month Results of a Nalmefene Phase-IV Trial.J Clin Med. 2019 Apr 6;8(4):471. doi: 10.3390/jcm8040471. J Clin Med. 2019. PMID: 30959893 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical